Since the loss of PSD-95 at synapses affects synaptic function and strength, we believe that molecules and signaling pathways, including post-translational modifications, which regulate the integrity of PSD-95, may have therapeutic potential for reducing synaptic loss and cognitive impairment in a wide range of diseases. The gene discussed is DLG4; the disease is Cognitive impairment.